Halicin

Overview

Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC 50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC 50 of 239 nM. Halicin shows less active against p38α and Akt kinase.

Application

Products | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lipid Metabolism | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > JNK

Product Information

• Catalog No.: HY-107597
• CAS No.: 40045-50-9
• Molecular Formula: C5H3N5O2S3
• Molecular Weight: 261.30
• Purity: 98.92%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (7.96 mM); Clear solution
• Availability: In-stock

Source

Original product source